Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monk

Showing results (61-70 of 738) with videos related to

Pageof 74
Sort By:
Gynecologic Oncology|February 1, 1993
Effectiveness of two barriers at inhibiting post-radical pelvic surgery adhesionsF J Montz, B J Monk, S M Lacy
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2013
Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent diseaseB J Monk, E Pujade-Lauraine, R A Burger
Gynecologic Oncology|June 1, 1992
The Gore-Tex Surgical Membrane: effectiveness as a barrier to inhibit postradical pelvic surgery adhesions in a porcine modelF J Montz, B J Monk, S M Lacy
Gynecologic Oncology|October 29, 2009
Anti-angiogenesis agents in metastatic or recurrent cervical cancerBradley J Monk, Lyndsay J Willmott, Daniele A Sumner
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2016
Anti-angiogenic agents in ovarian cancer: past, present, and futureB J Monk, L E Minion, R L Coleman
Current Pharmaceutical Design|May 6, 2016
Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer PatientsBradley J Monk, Thomas J Herzog, Krishnansu S Tewari
Journal of the National Comprehensive Cancer Network : JNCCN|December 15, 2010
Biologics in cervical cancer therapyLyndsay J Willmott, Daniele A Sumner, Bradley J Monk
Cancer Treatment Reviews|May 11, 2025
Optimal bevacizumab treatment strategy in advanced ovarian cancer: A reviewBradley J Monk, Domenica Lorusso, Keiichi Fujiwara, et al.
Current Pharmaceutical Design|May 18, 2012
Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancerBradley J Monk, Heather Dalton, Ivor Benjamin, et al.
British Journal of Anaesthesia|May 1, 1984
Effect of nitrous oxide on halothane-induced hepatotoxicity in hypoxic, enzyme-induced ratsJ A Ross, S J Monk, S W Duffy
Pageof 74

Showing results (61-70 of 738) with videos related to

Sort By:
Pageof 74
Gynecologic Oncology|February 1, 1993
Effectiveness of two barriers at inhibiting post-radical pelvic surgery adhesionsF J Montz, B J Monk, S M Lacy
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 23, 2013
Integrating bevacizumab into the management of epithelial ovarian cancer: the controversy of front-line versus recurrent diseaseB J Monk, E Pujade-Lauraine, R A Burger
Gynecologic Oncology|June 1, 1992
The Gore-Tex Surgical Membrane: effectiveness as a barrier to inhibit postradical pelvic surgery adhesions in a porcine modelF J Montz, B J Monk, S M Lacy
Gynecologic Oncology|October 29, 2009
Anti-angiogenesis agents in metastatic or recurrent cervical cancerBradley J Monk, Lyndsay J Willmott, Daniele A Sumner
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2016
Anti-angiogenic agents in ovarian cancer: past, present, and futureB J Monk, L E Minion, R L Coleman
Current Pharmaceutical Design|May 6, 2016
Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer PatientsBradley J Monk, Thomas J Herzog, Krishnansu S Tewari
Journal of the National Comprehensive Cancer Network : JNCCN|December 15, 2010
Biologics in cervical cancer therapyLyndsay J Willmott, Daniele A Sumner, Bradley J Monk
Cancer Treatment Reviews|May 11, 2025
Optimal bevacizumab treatment strategy in advanced ovarian cancer: A reviewBradley J Monk, Domenica Lorusso, Keiichi Fujiwara, et al.
Current Pharmaceutical Design|May 18, 2012
Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancerBradley J Monk, Heather Dalton, Ivor Benjamin, et al.
British Journal of Anaesthesia|May 1, 1984
Effect of nitrous oxide on halothane-induced hepatotoxicity in hypoxic, enzyme-induced ratsJ A Ross, S J Monk, S W Duffy
Pageof 74